{
  "chapter_title": "Business Activities",
  "section_title": "Operations",
  "description": "Main lines of business, products/services offered, revenue streams.",
  "questions": [
    {
      "question": "What products and services does Ion Beam Applications SA primarily offer, and how do they relate to the KYC and credit risk analysis?",
      "queries": [
        {
          "query": "Ion Beam Applications SA product offerings",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Ion Beam Applications SA service description",
          "results": [
            {
              "text": "ich will determine how the revenue is recognised. Equipment and installation services \nThe main activity of the Group consists of the construction of proton-therapy and other accelerators equipment and the \ninstallation services for its customers. Such contracts with customers are referred to as equipment and installation services, it represents the most important portion of IBAs revenue. Services \nThe Group provides operation and maintenance services which relate to the daily functioning and ma",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "KYC implications of Ion Beam Applications SA products",
          "results": [
            {
              "text": "ith IBA RadioPharma Solutions and Proton Therapy. The TSC serves as an intelligent knowledge repository \nfacilitating efficient knowledge sharing, accelerating \ntroubleshooting processes, and fostering autonomy in \nproblem-solving endeavors. E-BEAM AND X-RAY IRRADIATION IS \nRECOGNIZED AS THE SAFEST TECHNOLOGY \nTO HANDLE THE GROWTH OF THE MEDICAL \nDEVICE INDUSTRY\nThe medical device industry has a wide range of products that \nenable patient diagnosis and treatment.",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What are the main revenue streams for Ion Beam Applications SA, and how do they impact the credit risk assessment?",
      "queries": [
        {
          "query": "Ion Beam Applications SA revenue streams",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Ion Beam Applications SA business model analysis",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Credit risk implications of Ion Beam Applications SA revenue",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "What specific operational factors could influence Ion Beam Applications SA's ability to manage KYC and credit risk?",
      "queries": [
        {
          "query": "Ion Beam Applications SA operational risks",
          "results": [
            {
              "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "KYC and credit risk management in Ion Beam Applications SA",
          "results": [
            {
              "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Operational challenges for Ion Beam Applications SA",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    },
    {
      "question": "Are there any notable partnerships, collaborations, or affiliations that could impact Ion Beam Applications SA's KYC and credit risk posture?",
      "queries": [
        {
          "query": "Ion Beam Applications SA partnerships analysis",
          "results": [
            {
              "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Collaborations impacting Ion Beam Applications SA KYC",
          "results": [
            {
              "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
              "source": "",
              "score": 0.0
            }
          ]
        },
        {
          "query": "Affiliations influencing Ion Beam Applications SA credit risk",
          "results": [
            {
              "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
              "source": "",
              "score": 0.0
            }
          ]
        }
      ]
    }
  ]
}